Revised labeling warns of vitamin B6 deficiency-related seizures in carbidopa/levodopa users, suggesting monitoring.
A new warning has been added to the labeling of carbidopa/levodopa products regarding the risk of vitamin B6 deficiency–associated seizures. These seizures may not respond to antiepileptic drug therapy. The revised labeling recommends assessment of vitamin B6 levels prior to and throughout therapy with carbidopa/levodopa.
No takes yet. Share an insight, caveat, or question.
Diane S. Aschenbrenner (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: